Partnering with Artax
Our pipeline of first-in-class Nck modulator candidates is fully proprietary, with a convincing clinical and preclinical data package. We reported clinical validation of Nck modulation with AX-158 in Phase 2a in psoriasis patients.
Novel mechanism of action effective across multiple diseases and strong composition of matter patent protection
Our pipeline of Nck modulators is breaking new ground across a wide array of T cell mediated autoimmune indications.
Interested in partnering with us? Get in touch!
We are interested in speaking with potential pharma partners about further development and commercialization of our first-in-class pipeline. Contact us at contact@artaxbiopharma.com
The latest news and publications from Artax
-
- Press Releases
Artax Biopharma to present Phase 2a data on Nck modulatorAX-158, establishing novel mechanism of action in autoimmune disease at the 2025 SID Annual Meeting
Late breaker abstract presentation to showcase clinical validation of first-in-class oral small molecule AX-158 in… -
- Media
In Search of the Universal T-cell Modulator for Skin Diseases: Exploring the Role of Nck With Christopher VanDeusen, PhD
-
- Press Releases
Artax Biopharma presents new preclinical data on Nck modulators at 2025 AAD Annual Meeting
Cambridge, MA, March 7, 2025 – Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the…